Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 16/20 | 0.67 |
| ▸ | MMP9 | P14780 | 15/20 | 0.67 |
| ▸ | MMP1 | P03956 | 12/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.63 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813864 | 0.91 | MMP13 (0.68) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL7317407 | 0.90 | MMP13 (0.83) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL7316882 | 0.89 | MMP13 (0.63) | MMP13MMP9MMP1ADAM17NR3C1 | |
| SCHEMBL7317150 | 0.88 | MMP13 (0.78) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL6819082 | 0.83 | MMP13 (0.65) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL7324366 | 0.82 | MMP13 (0.72) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL7322655 | 0.81 | MMP13 (0.83) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL7307450 | 0.81 | MMP13 (0.61) | MMP13MMP9MMP1ADAM17PSEN1 | |
| SCHEMBL7315395 | 0.80 | MMP13 (0.72) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL7313797 | 0.80 | MMP13 (0.72) | MMP13MMP9MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470794-B2 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825352-B2 | ANTIARTHRITIC, ANTITUMOR, ANTIMETASTASIS, ANTIULCER, AND WOUND HEALING AGENTS; BONE, NERVOUS SYSTEM, DEGENERATIVE JOINT DISORDERS; PROTEINURIA, ANEURYSMS, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS | WYETH | 2004-11-30 | — | — | US | disclosed |
| EP-1144369-B1 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6762178-B2 | FOR USE IN TREATMENT OF DISEASE CONDITIONS MEDIATED BY TNF-ALPHA, SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE, DEGENERATIVE CARTILAGE LOSS | WYETH HOLDINGS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | disclosed |
| EP-1259488-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | disclosed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID COMPANY (US) | 2001-12-27 | — | — | US | disclosed |
| EP-0938471-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1144369-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001062733-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6277885-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY | 2001-08-21 | — | — | US | disclosed |
| WO-2000044710-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| CN-1240429-A | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0938471-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5929097-A | INHIBIT TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1998016503-A2 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP7, MMP2 | MMP13 9/4885MMP9 21/4885MMP1 1/4885 |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | PTDSS1, SAT1, TNF | MMP13 254/4885MMP9 507/4885MMP1 255/4885 |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | MMP1, MMP7, MMP2 | MMP13 9/4885MMP9 21/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.